Abstract 14486: Comparative Cardiovascular and Mortality Outcomes of GLP-1 Receptor Agonists versus SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Propensity Score-Matched Cohort Study
GLP-1 RA therapy was associated with significantly lower risks of major adverse cardiovascular outcomes and all-cause mortality compared with SGLT2 inhibitors, suggesting a potential advantage of GLP-1 RA therapy for long-term cardiovascular risk reduction in patients with T2DM.
Abstract
Background:
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) are widely used in the management of type 2 diabetes mellitus (T2DM) and have demonstrated cardiovascular benefits. However, real-world comparative data evaluating major cardiovascular outcomes and mortality between these therapeutic classes remain limited. We compared cardiovascular and mortality outcomes among patients with T2DM receiving GLP-1 RAs versus SGLT2 inhibitors.
Methods:
We conducted a retrospective cohort study using the TriNetX Research Network. Adult patients with T2DM receiving GLP-1 RAs without SGLT2 inhibitors were compared with patients receiving SGLT2 inhibitors without GLP-1 RAs. After propensity score matching, 419,760 patients were included in each cohort. Outcomes assessed from 1 day after treatment initiation included myocardial infarction (MI), atherosclerosis, cerebral infarction, heart failure (HF), and all-cause mortality. Risk ratios (RRs) and hazard ratios (HRs) were calculated.
Results:
Following matching, GLP-1 RA therapy was associated with significantly lower risks of all evaluated outcomes compared with SGLT2 inhibitors. Patients receiving GLP-1 RAs had lower risks of MI (4.1% vs 7.8%; RR 0.52, HR 0.49), atherosclerosis (6.7% vs 7.9%; RR 0.84, HR 0.80), cerebral infarction (4.8% vs 6.3%; RR 0.77, HR 0.73), HF (12.2% vs 25.0%; RR 0.49, HR 0.43), and all-cause mortality (6.0% vs 7.3%; RR 0.82, HR 0.77) (all p<0.001).
Conclusions:
In this large propensity score-matched real-world cohort of patients with T2DM, GLP-1 receptor agonists were associated with significantly lower risks of major adverse cardiovascular outcomes and all-cause mortality compared with SGLT2 inhibitors. These findings suggest a potential advantage of GLP-1 RA therapy for long-term cardiovascular risk reduction in patients with T2DM.
Background:
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and dipeptidyl peptidase-4 inhibitors (DPP4i) are commonly used second-line agents in type 2 diabetes mellitus (T2DM). This large-scale real-world analysis compared their effects on major cardiovascular, renal, and diabetes-related complications.
Me...
Sajjad Ahmed Khan, Anurag Marasini· Circulation· 0 citations
In patients with prior MI and overweight or obesity, GLP-1 RA use was associated with substantially lower risk of MACE and new-onset heart failure than SGLT2i, with consistent benefit across ischemic and pulmonary vascular outcomes and neutral effects on mortality.
Zaid Al-Kofahi, H. Alhammouri, F. Qtaishat et al.· Circulation· 0 citations
Background:
Glucagon-like peptide-1 receptor agonists (GLP1RA) and dipeptidyl peptidase-4 inhibitors (DPP4i) are commonly used second-line agents in type 2 diabetes mellitus (T2DM). This large-scale real-world analysis compared their effects on major clinical outcomes.
Methods:
Using the TriNetX Research netwo...
Sajjad Ahmed Khan, Anurag Marasini· Circulation· 0 citations
Background:
Both glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) provide cardiovascular benefits in type 2 diabetes (T2D). While SGLT2i is a cornerstone therapy for heart failure with preserved ejection fraction (HFpEF), the incremental prognostic benefit of...
A. Bielecka-Dąbrowa, M. Banach, Akash Jaiswal et al.· Circulation· 0 citations
Background:
Patients with type 2 diabetes mellitus (T2DM), heart failure (HF), and chronic kidney disease (CKD) remain at high risk for renal deterioration, glycaemic emergencies, and adverse cardiovascular outcomes despite contemporary therapy. Although sodium-glucose cotransporter-2 inhibitors (SGLT2i) improve car...
Emmanuel Adjei-Wiafe, G. Blankson, E. Ansah et al.· Circulation· 0 citations
Background:
According to the European Society of Cardiology (ESC) guidelines, both GLP-1 receptor agonists and SGLT2 inhibitors have documented cardiovascular benefits in patients with type 2 diabetes mellitus (T2DM), with SGLT2 inhibitors particularly recommended to reduce heart failure hospitalizations. However, r...
Vikash Jaiswal, M. Banach, Akash Jaiswal et al.· Circulation· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.